Literature DB >> 29395675

Congenital myasthenic syndromes in Turkey: Clinical clues and prognosis with long term follow-up.

Hacer Durmus1, Xin-Ming Shen2, Piraye Serdaroglu-Oflazer1, Bulent Kara1, Yesim Parman-Gulsen1, Coskun Ozdemir1, Joan Brengman2, Feza Deymeer3, Andrew G Engel2.   

Abstract

Congenital myasthenic syndromes (CMS) are a group of hereditary disorders affecting the neuromuscular junction. Here, we present clinical, electrophysiological and genetic findings of 69 patients from 51 unrelated kinships from Turkey. Genetic tests of 60 patients were performed at Mayo Clinic. Median follow-up time was 9.8 years (range 1-22 years). The most common CMS was primary acetylcholine receptor (AChR) deficiency (31/51) and the most common mutations in AChR were c.1219 + 2T > G (12/51) and c.1327delG (6/51) in CHRNE. Four of our 5 kinships with AChE deficiency carried p.W148X that truncates the collagen domain of COLQ, and was previously reported only in patients from Turkey. These were followed by GFPT1 deficiency (4/51), DOK7 deficiency (3/51), slow channel CMS (3/51), fast channel CMS (3/51), choline acetyltransferase deficiency (1/51) and a CMS associated with desmin deficiency (1/51). Distribution of muscle weakness was sometimes useful in giving a clue to the CMS subtype. Presence of repetitive compound muscle action potentials pointed to AChE deficiency or slow channel CMS. Our experience confirms that one needs to be cautious using pyridostigmine, since it can worsen some types of CMS. Ephedrine/salbutamol were very effective in AChE and DOK7 deficiencies and were useful as adjuncts in other types of CMS. Long follow-up gave us a chance to assess progression of the disease, and to witness 12 mainly uneventful pregnancies in 8 patients. In this study, we describe some new phenotypes and detail the clinical features of the well-known CMS.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Congenital myasthenic syndromes; Genetic; Myasthenia; Turkey

Mesh:

Substances:

Year:  2017        PMID: 29395675      PMCID: PMC5924610          DOI: 10.1016/j.nmd.2017.11.013

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  38 in total

Review 1.  Congenital myasthenic syndromes: spotlight on genetic defects of neuromuscular transmission.

Authors:  Juliane S Müller; Violeta Mihaylova; Angela Abicht; Hanns Lochmüller
Journal:  Expert Rev Mol Med       Date:  2007-08-09       Impact factor: 5.600

2.  A common mutation (epsilon1267delG) in congenital myasthenic patients of Gypsy ethnic origin.

Authors:  A Abicht; R Stucka; V Karcagi; A Herczegfalvi; R Horváth; W Mortier; U Schara; V Ramaekers; W Jost; J Brunner; G Janssen; U Seidel; B Schlotter; W Müller-Felber; D Pongratz; R Rüdel; H Lochmüller
Journal:  Neurology       Date:  1999-10-22       Impact factor: 9.910

3.  Myasthenic syndromes in Turkish kinships due to mutations in the acetylcholine receptor.

Authors:  K Ohno; B Anlar; E Ozdirim; J M Brengman; J L DeBleecker; A G Engel
Journal:  Ann Neurol       Date:  1998-08       Impact factor: 10.422

4.  Neuromuscular endplate pathology in recessive desminopathies: Lessons from man and mice.

Authors:  Hacer Durmuş; Özgecan Ayhan; Sebahattin Çırak; Feza Deymeer; Yeşim Parman; Andre Franke; Nane Eiber; Frederic Chevessier; Ursula Schlötzer-Schrehardt; Christoph S Clemen; Said Hashemolhosseini; Rolf Schröder; Georg Hemmrich-Stanisak; Aslıhan Tolun; Piraye Serdaroğlu-Oflazer
Journal:  Neurology       Date:  2016-07-20       Impact factor: 9.910

5.  Congenital endplate acetylcholinesterase deficiency.

Authors:  D O Hutchinson; T J Walls; S Nakano; S Camp; P Taylor; C M Harper; R V Groover; H A Peterson; D G Jamieson; A G Engel
Journal:  Brain       Date:  1993-06       Impact factor: 13.501

6.  Human endplate acetylcholinesterase deficiency caused by mutations in the collagen-like tail subunit (ColQ) of the asymmetric enzyme.

Authors:  K Ohno; J Brengman; A Tsujino; A G Engel
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

7.  Mutation in the human acetylcholinesterase-associated collagen gene, COLQ, is responsible for congenital myasthenic syndrome with end-plate acetylcholinesterase deficiency (Type Ic).

Authors:  C Donger; E Krejci; A P Serradell; B Eymard; S Bon; S Nicole; D Chateau; F Gary; M Fardeau; J Massoulié; P Guicheney
Journal:  Am J Hum Genet       Date:  1998-10       Impact factor: 11.025

8.  Congenital myasthenic syndrome with tubular aggregates caused by GFPT1 mutations.

Authors:  Velina Guergueltcheva; Juliane S Müller; Marina Dusl; Jan Senderek; Anders Oldfors; Christopher Lindbergh; Susan Maxwell; Jaume Colomer; Cecilia Jimenez Mallebrera; Andres Nascimento; Juan J Vilchez; Nuria Muelas; Janbernd Kirschner; Shahriar Nafissi; Ariana Kariminejad; Yalda Nilipour; Bita Bozorgmehr; Hossein Najmabadi; Carmelo Rodolico; Jörn P Sieb; Beate Schlotter; Benedikt Schoser; Ralf Herrmann; Thomas Voit; Ortrud K Steinlein; Abdolhamid Najafi; Andoni Urtizberea; Doriette M Soler; Francesco Muntoni; Michael G Hanna; Amina Chaouch; Volker Straub; Kate Bushby; Jacqueline Palace; David Beeson; Angela Abicht; Hanns Lochmüller
Journal:  J Neurol       Date:  2011-10-06       Impact factor: 4.849

Review 9.  Congenital myasthenic syndromes: recent advances.

Authors:  David Beeson
Journal:  Curr Opin Neurol       Date:  2016-10       Impact factor: 5.710

10.  Clinical features of the DOK7 neuromuscular junction synaptopathy.

Authors:  Jacqueline Palace; Daniel Lashley; John Newsom-Davis; Judy Cossins; Susan Maxwell; Robin Kennett; Sandeep Jayawant; Yuji Yamanashi; David Beeson
Journal:  Brain       Date:  2007-04-23       Impact factor: 13.501

View more
  7 in total

1.  Rare slow channel congenital myasthenic syndromes without repetitive compound muscle action potential and dramatic response to low dose fluoxetine.

Authors:  Hacer Durmus; Heinrich Sticht; Serdar Ceylaner; Said Hashemolhosseini; Feza Deymeer
Journal:  Acta Neurol Belg       Date:  2020-10-08       Impact factor: 2.396

2.  Clinicopathological-genetic features of congenital myasthenic syndrome from a Chinese neuromuscular centre.

Authors:  Kun Huang; Hui-Qian Duan; Qiu-Xiang Li; Yue-Bei Luo; Fang-Fang Bi; Huan Yang
Journal:  J Cell Mol Med       Date:  2022-06-06       Impact factor: 5.295

3.  Determinants of the repetitive-CMAP occurrence and therapy efficacy in slow-channel myasthenia.

Authors:  Li Di; Hai Chen; Yan Lu; Duygu Selcen; Andrew G Engel; Yuwei Da; Xin-Ming Shen
Journal:  Neurology       Date:  2020-09-09       Impact factor: 9.910

4.  Targeted therapies for congenital myasthenic syndromes: systematic review and steps towards a treatabolome.

Authors:  Rachel Thompson; Gisèle Bonne; Paolo Missier; Hanns Lochmüller
Journal:  Emerg Top Life Sci       Date:  2019-01-28

5.  Slow-channel myasthenia due to novel mutation in M2 domain of AChR delta subunit.

Authors:  Xin-Ming Shen; Margherita Milone; Hang-Long Wang; Brenda Banwell; Duygu Selcen; Steven M Sine; Andrew G Engel
Journal:  Ann Clin Transl Neurol       Date:  2019-09-27       Impact factor: 4.511

6.  Long Term Follow-Up on Pediatric Cases With Congenital Myasthenic Syndromes-A Retrospective Single Centre Cohort Study.

Authors:  Adela Della Marina; Eva Wibbeler; Angela Abicht; Heike Kölbel; Hanns Lochmüller; Andreas Roos; Ulrike Schara
Journal:  Front Hum Neurosci       Date:  2020-12-07       Impact factor: 3.169

7.  Abnormal decrement on high-frequency repetitive nerve stimulation in congenital myasthenic syndrome with GFPT1 mutations and review of literature.

Authors:  Ran An; Huijiao Chen; Song Lei; Yi Li; Yanming Xu; Chengqi He
Journal:  Front Neurol       Date:  2022-09-15       Impact factor: 4.086

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.